Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Vo L. Amin A, et al. Among authors: mardekian j. Curr Med Res Opin. 2017 Sep;33(9):1595-1604. doi: 10.1080/03007995.2017.1345729. Epub 2017 Jul 11. Curr Med Res Opin. 2017. PMID: 28635338
Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation.
Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Lingohr-Smith M, Menges B, Lin J. Deitelzweig S, et al. Among authors: mardekian j. J Manag Care Spec Pharm. 2017 Nov;23(11):1191-1201. doi: 10.18553/jmcp.2017.17060. Epub 2017 Aug 11. J Manag Care Spec Pharm. 2017. PMID: 29083968 Free PMC article.
Correction to: Steven Deitelzweig et al., Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Deitelzweig S, Luo X, Gupta K, Mardekian J, Trocio JN, Curtice T, Lingohr-Smith M, Menges B, Lin J. Deitelzweig S, et al. Among authors: mardekian j. Curr Med Res Opin. 2018 Jan;34(1):11-12. doi: 10.1080/03007995.2017.1397989. Epub 2017 Nov 2. Curr Med Res Opin. 2018. PMID: 29095647 No abstract available.
All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants.
Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Hlavacek P, Lingohr-Smith M, Menges B, Lin J. Deitelzweig S, et al. Among authors: mardekian j. Clin Appl Thromb Hemost. 2018 May;24(4):602-611. doi: 10.1177/1076029617750269. Epub 2018 Jan 24. Clin Appl Thromb Hemost. 2018. PMID: 29363999 Free PMC article.
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach.
Li X, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH, Deitelzweig S. Li X, et al. Among authors: mardekian j. PLoS One. 2018 Jan 26;13(1):e0191722. doi: 10.1371/journal.pone.0191722. eCollection 2018. PLoS One. 2018. PMID: 29373602 Free PMC article.
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Nadkarni A, Vo L. Amin A, et al. Among authors: mardekian j. J Manag Care Spec Pharm. 2018 Sep;24(9):911-920. doi: 10.18553/jmcp.2018.24.9.911. J Manag Care Spec Pharm. 2018. PMID: 30156450 Free PMC article. Clinical Trial.
160 results